Barclays’s Serina Therapeutics SER Stock Holding History

Barclays’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06K	Buy	+545	New	+$1.02K	﹤0.01%	4924
2021 Q3	–	Sell	-1,169	Closed	-$64K	–	5066
2021 Q2	$64K	Hold	1,169	–	–	﹤0.01%	4027
2021 Q1	$67K	Hold	1,169	–	–	﹤0.01%	4135
2020 Q4	$62K	Hold	1,169	–	–	﹤0.01%	4325
2020 Q3	$33K	Sell	1,169 -173	-13%	-$6.17K	﹤0.01%	4773
2020 Q2	$45K	Sell	1,342 -27	-2%	-$795	﹤0.01%	4979
2020 Q1	$44K	Buy	1,369 +764	+126%	+$35.9K	﹤0.01%	5306
2019 Q4	$39K	Buy	605 +304	+101%	+$16.4K	﹤0.01%	5814
2019 Q3	$21K	Sell	301 -92	-23%	-$8.73K	﹤0.01%	6203
2019 Q2	$50K	Buy	393 +253	+181%	+$34.3K	﹤0.01%	6098
2019 Q1	$19K	Buy	140 +133	+1,900%	+$19.4K	﹤0.01%	6381
2018 Q4	$0	Buy	+7	New	+$890	﹤0.01%	7403

Other funds holding SER

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Waverly Advisors Birmingham, Alabama $17.2B AUM 24.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keel Point Huntsville, Alabama $1.69B AUM 20.79% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AWE

Avidian Wealth Enterprises Houston, Texas $3.62B AUM 24.8% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's SER Position: Q2 2026 in Review

Barclays opened a new position in Serina Therapeutics (SER) in Q2 2026: 545 shares worth $1.06K. The stake represents ﹤0.01% of the portfolio and ranks #4924 among its holdings. This is a return to the name: Barclays previously reported a position in SER as recently as Q2 2021.

Barclays first reported a position in SER in Q4 2018 and has held it in 12 quarters since. The position peaked at $67K in Q1 2021. 27 funds tracked by Wall St. Rank hold SER as of Q2 2026.

Barclays held 545 shares of Serina Therapeutics worth $1.06K as of Q2 2026.
Serina Therapeutics was a new Barclays position in Q2 2026.
Serina Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4924 holding.
Barclays first reported a position in Serina Therapeutics in Q4 2018 and has held it in 12 quarters since.
Barclays's Serina Therapeutics position peaked at $67K in Q1 2021.
27 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.